BRIEF published on 01/23/2026 at 07:05, 4 months 26 days ago BB Biotech AG Reports Significant Profit for 2025 Investment Company BB Biotech AG Drug Developers 2025 Profit Share Price Development
BRIEF published on 01/23/2026 at 07:05, 4 months 26 days ago BB Biotech Reports Strong Preliminary 2025 Results and Dividend Proposal Dividend Proposal Share Performance BB Biotech Biotech Investment 2025 Financial Results
PRESS RELEASE published on 01/23/2026 at 07:00, 4 months 26 days ago EQS-Adhoc: BB Biotech AG closes the 2025 fiscal year with a profit BB Biotech AG closes the 2025 fiscal year with a profit of approximately CHF 578 million, reflecting share price development. Full report on Feb 20, 2026 BB Biotech AG Profit 2025 Fiscal Year Share Price Development CHF 578 Million
PRESS RELEASE published on 01/23/2026 at 07:00, 4 months 26 days ago BB Biotech: Preliminary full-year 2025 results and dividend proposal BB Biotech AG reports strong full-year 2025 results with +34.2% total return in CHF, +37.0% in EUR, and +53.7% in USD, proposes dividend of CHF 2.25 per share at AGM on March 19, 2026 Dividend Proposal Stock Market Full-year Results BB Biotech AG 2025 Performance
BRIEF published on 10/28/2025 at 13:20, 7 months 21 days ago BB Biotech Outperforms with Strong Q3 2025 Results Biotech Sector M&A BB Biotech Q3 2025 Nasdaq Biotech Index
PRESS RELEASE published on 10/28/2025 at 13:15, 7 months 21 days ago Edison issues report on BB Biotech (BION) Edison issues positive report on BB Biotech (BION) with strong Q325 results, outperforming its benchmark. Sector outlook remains favorable with M&A as key performance driver Edison M&A BB Biotech Outperforming Q325 Results
BRIEF published on 10/24/2025 at 07:05, 7 months 25 days ago BB Biotech AG Releases Interim Report Highlighting Significant Profit Increase Investment Company BB Biotech AG Interim Report Net Profit Increase Drug Developers
BRIEF published on 10/24/2025 at 07:05, 7 months 25 days ago BB Biotech's Q3 2025 Outperformance Amid Sector Recovery Sector Recovery BB Biotech Q3 2025 Performance Nasdaq Biotechnology Index RNA-based Therapeutics
PRESS RELEASE published on 10/24/2025 at 07:00, 7 months 25 days ago EQS-Adhoc: BB Biotech AG publishes its interim report BB Biotech AG publishes interim report for the first nine months of 2025, reporting CHF 106 mn net profit. More details at report.bbbiotech.ch/Q325 Financial Results Investment Company Net Profit BB Biotech AG Interim Report
PRESS RELEASE published on 10/24/2025 at 07:00, 7 months 25 days ago BB Biotech Q3 2025: Portfolio outperformance amid early signs of sector recovery BB Biotech AG reports strong Q3 2025 performance with portfolio outperforming Nasdaq Biotech Index, driven by solid net profit, key company milestones, and strategic investments BB Biotech AG Interim Report Sector Recovery Q3 2025 Portfolio Outperformance
Published on 06/18/2026 at 18:00, 3 hours 54 minutes ago BEACN Closes Second Series Under Loan Program and Previews BEACN App Version 1.4
Published on 06/18/2026 at 17:30, 4 hours 24 minutes ago Sekur Private Data Appoints Nathan R. Price as Special Advisor for Diplomacy & Intelligence
Published on 06/18/2026 at 15:50, 6 hours 4 minutes ago Pentagon I Capital Corp. and Prospectiva Resources Ltd. Announce Financing
Published on 06/18/2026 at 15:00, 6 hours 54 minutes ago Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Announces Positive Results of Preclinical Study of Coca for Weight Gain Prevention
Published on 06/18/2026 at 14:30, 7 hours 24 minutes ago Voting Results from Solitario Resources Corp Annual Meeting Held June 17, 2026
Published on 06/18/2026 at 18:30, 3 hours 23 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 06/18/2026 at 18:25, 3 hours 28 minutes ago Sopra Steria achives Level 2 Responsible Digital Label and strengthens its responsible digital strategy
Published on 06/18/2026 at 17:45, 4 hours 8 minutes ago 2CRSi SA: 2CRSi disputes the content of the document published by Grizzly Research and is preparing a substantiated response calling for the suspension of trading in its shares
Published on 06/18/2026 at 18:00, 3 hours 54 minutes ago Outstanding shares and voting rights statement at 31 May 2026
Published on 06/18/2026 at 17:45, 4 hours 9 minutes ago EURAZEO INVESTS IN LAURALU, A PAN-EUROPEAN PROVIDER OF DEPLOYABLE INDUSTRIAL INFRASTRUCTURE
Published on 06/18/2026 at 17:38, 4 hours 15 minutes ago Statement of transactions in own shares from June 8, 2026 to June 12, 2026
Published on 06/18/2026 at 09:06, 12 hours 47 minutes ago Eiffage, member of the NSORe joint venture, wins the contract for a converter station for the NSC2 offshore grid connection project in Germany
